share_log

Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Fitzgerald Thomas A

SEC announcement ·  Jun 19 04:22
Summary by Futu AI
Interim CEO and CFO of Transcode Therapeutics, Inc., Fitzgerald Thomas A, has engaged in a transaction involving the company's stock, as reported on June 14, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action reflects a change in the holdings of Fitzgerald Thomas A, which could be of interest to investors of Transcode Therapeutics, Inc. [RNAZ].
Interim CEO and CFO of Transcode Therapeutics, Inc., Fitzgerald Thomas A, has engaged in a transaction involving the company's stock, as reported on June 14, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action reflects a change in the holdings of Fitzgerald Thomas A, which could be of interest to investors of Transcode Therapeutics, Inc. [RNAZ].
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.